vs
雅培（ABT）与Arbutus Biopharma Corp（ABUS）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是Arbutus Biopharma Corp的10902.9倍（$11.5B vs $1.1M）。雅培同比增速更快（4.4% vs -33.2%）。过去两年雅培的营收复合增速更高（7.2% vs -17.2%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
Arbutus生物制药是一家公开上市的加拿大生物制药企业，专长于脂质体药物递送与RNA干扰技术，目前主要开展针对乙型肝炎感染的治疗药物研发工作，在抗病毒新药研发领域拥有深厚的技术积累。
ABT vs ABUS — 直观对比
营收规模更大
ABT
是对方的10902.9倍
$1.1M
营收增速更快
ABT
高出37.6%
-33.2%
两年增速更快
ABT
近两年复合增速
-17.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.1M |
| 净利润 | $1.8B | — |
| 毛利率 | 57.0% | — |
| 营业利润率 | 19.6% | -503.3% |
| 净利率 | 15.5% | — |
| 营收同比 | 4.4% | -33.2% |
| 净利润同比 | -80.8% | — |
| 每股收益（稀释后） | $1.01 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTABUS
| Q4 25 | $11.5B | $1.1M | ||
| Q3 25 | $11.4B | $529.0K | ||
| Q2 25 | $11.1B | $10.7M | ||
| Q1 25 | $10.4B | $1.8M | ||
| Q4 24 | $11.0B | $1.6M | ||
| Q3 24 | $10.6B | $1.3M | ||
| Q2 24 | $10.4B | $1.7M | ||
| Q1 24 | $10.0B | $1.5M |
净利润ABTABUS
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | $-7.7M | ||
| Q2 25 | $1.8B | $2.5M | ||
| Q1 25 | $1.3B | $-24.5M | ||
| Q4 24 | $9.2B | — | ||
| Q3 24 | $1.6B | $-19.7M | ||
| Q2 24 | $1.3B | $-19.8M | ||
| Q1 24 | $1.2B | $-17.9M |
毛利率ABTABUS
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 55.2% | — |
营业利润率ABTABUS
| Q4 25 | 19.6% | -503.3% | ||
| Q3 25 | 18.1% | -1636.9% | ||
| Q2 25 | 18.4% | 13.9% | ||
| Q1 25 | 16.3% | -1456.9% | ||
| Q4 24 | 17.4% | -885.2% | ||
| Q3 24 | 17.5% | -1601.2% | ||
| Q2 24 | 16.1% | -1250.5% | ||
| Q1 24 | 13.9% | -1263.9% |
净利率ABTABUS
| Q4 25 | 15.5% | — | ||
| Q3 25 | 14.5% | -1463.5% | ||
| Q2 25 | 16.0% | 23.5% | ||
| Q1 25 | 12.8% | -1390.4% | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 15.5% | -1472.5% | ||
| Q2 24 | 12.5% | -1146.9% | ||
| Q1 24 | 12.3% | -1166.8% |
每股收益（稀释后）ABTABUS
| Q4 25 | $1.01 | $-0.01 | ||
| Q3 25 | $0.94 | $-0.04 | ||
| Q2 25 | $1.01 | $0.01 | ||
| Q1 25 | $0.76 | $-0.13 | ||
| Q4 24 | $5.26 | $-0.07 | ||
| Q3 24 | $0.94 | $-0.10 | ||
| Q2 24 | $0.74 | $-0.11 | ||
| Q1 24 | $0.70 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $91.5M |
| 总债务越低越好 | $12.9B | $0 |
| 股东权益账面价值 | $52.1B | $76.6M |
| 总资产 | $86.7B | $94.6M |
| 负债/权益比越低杠杆越低 | 0.25× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资ABTABUS
| Q4 25 | $8.9B | $91.5M | ||
| Q3 25 | $7.7B | $22.4M | ||
| Q2 25 | $7.3B | $37.4M | ||
| Q1 25 | $6.8B | $37.1M | ||
| Q4 24 | $8.0B | $122.6M | ||
| Q3 24 | $7.8B | $31.8M | ||
| Q2 24 | $7.2B | $62.8M | ||
| Q1 24 | $6.7B | $43.1M |
总债务ABTABUS
| Q4 25 | $12.9B | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | $14.1B | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益ABTABUS
| Q4 25 | $52.1B | $76.6M | ||
| Q3 25 | $51.0B | $77.4M | ||
| Q2 25 | $50.6B | $83.0M | ||
| Q1 25 | $48.8B | $79.2M | ||
| Q4 24 | $47.7B | $97.4M | ||
| Q3 24 | $39.8B | $106.9M | ||
| Q2 24 | $39.3B | $122.5M | ||
| Q1 24 | $38.8B | $114.6M |
总资产ABTABUS
| Q4 25 | $86.7B | $94.6M | ||
| Q3 25 | $84.2B | $97.7M | ||
| Q2 25 | $84.0B | $103.3M | ||
| Q1 25 | $81.4B | $117.0M | ||
| Q4 24 | $81.4B | $131.7M | ||
| Q3 24 | $74.4B | $140.4M | ||
| Q2 24 | $73.0B | $160.0M | ||
| Q1 24 | $72.5B | $150.3M |
负债/权益比ABTABUS
| Q4 25 | 0.25× | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | 0.30× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $-4.7M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | — |
| 自由现金流率自由现金流/营收 | 22.9% | — |
| 资本支出强度资本支出/营收 | 6.0% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.87× | — |
| 过去12个月自由现金流最近4个季度 | $7.4B | — |
8季度趋势，按日历期对齐
经营现金流ABTABUS
| Q4 25 | $3.3B | $-4.7M | ||
| Q3 25 | $2.8B | $-5.8M | ||
| Q2 25 | $2.0B | $-15.7M | ||
| Q1 25 | $1.4B | $-13.4M | ||
| Q4 24 | $2.9B | $-10.3M | ||
| Q3 24 | $2.7B | $-20.7M | ||
| Q2 24 | $2.0B | $-14.5M | ||
| Q1 24 | $1.0B | $-19.3M |
自由现金流ABTABUS
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $933.0M | — | ||
| Q4 24 | $2.1B | $-10.4M | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | $-14.5M | ||
| Q1 24 | $627.0M | $-19.4M |
自由现金流率ABTABUS
| Q4 25 | 22.9% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 19.6% | -660.8% | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 13.8% | -840.4% | ||
| Q1 24 | 6.3% | -1265.7% |
资本支出强度ABTABUS
| Q4 25 | 6.0% | 0.0% | ||
| Q3 25 | 4.4% | 0.0% | ||
| Q2 25 | 4.5% | 0.0% | ||
| Q1 25 | 4.7% | 0.0% | ||
| Q4 24 | 6.6% | 5.5% | ||
| Q3 24 | 5.2% | 0.0% | ||
| Q2 24 | 5.1% | 0.1% | ||
| Q1 24 | 4.0% | 6.2% |
现金转化率ABTABUS
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | -6.24× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
